A team of researchers from UCLA has created a new blood test that may change how doctors detect cancer and other diseases.
Their findings, published in the Proceedings of the National Academy of Sciences, suggest that a simple blood sample could provide a wide view of a person’s health.
Early detection of disease is one of the most important goals in medicine. Many serious illnesses, including cancer, are easier to treat when found early. However, current screening methods often focus on one disease at a time and can be costly or uncomfortable.
The new test, called MethylScan, works by analyzing small fragments of DNA that circulate in the blood. These fragments come from cells all over the body. When cells die, they release their DNA into the bloodstream, carrying information about their condition.
What makes this test different is that it looks at DNA methylation. These are chemical markers on DNA that change depending on the health of the cells. Healthy and diseased tissues have different methylation patterns, which can be detected and analyzed.
One major problem with blood-based testing is that most DNA in the blood comes from normal cells. This creates a lot of background noise, making it hard to detect signals from cancer or damaged organs.
To overcome this, the researchers developed a method to remove much of the unwanted DNA. By focusing on the most informative DNA fragments, they were able to improve accuracy and reduce costs.
The team tested the method on more than 1,000 participants, including cancer patients, people with liver disease, and healthy individuals. They used advanced computer analysis to interpret the complex data.
The test showed strong results. It detected around 63% of cancers overall and more than half of early-stage cancers. For liver cancer, especially in high-risk groups, the detection rate was close to 80%.
Another useful feature is that the test can identify which organ is affected. This helps guide doctors toward the right follow-up tests, making diagnosis more efficient.
The researchers also found that the test could tell different types of liver disease apart with good accuracy. This could reduce the need for invasive procedures like liver biopsies.
While these results are promising, the test is still in the early stages of development. Larger studies are needed to confirm how well it works in everyday clinical settings.
From an analytical perspective, this study introduces a practical and scalable approach to disease detection. By focusing on methylation instead of mutations, it avoids some of the limitations of current methods.
However, the sensitivity for early-stage cancer is still moderate, meaning some cases may not be detected. Improving this will be key for real-world use. Cost advantages are a major strength, but clinical validation is still required.
In conclusion, this research moves us closer to a future where a single blood test could provide a full picture of a person’s health. It has the potential to improve early detection, reduce costs, and make healthcare more accessible.
If you care about cancer, please read studies that artificial sweeteners are linked to higher cancer risk, and how drinking milk affects risks of heart disease and cancer.
For more health information, please see recent studies about the best time to take vitamins to prevent heart disease, and results showing vitamin D supplements strongly reduces cancer death.
Source: University of California, Los Angeles (UCLA).
